Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.37 |
| ▸ | TK1 | P04183 | 4/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822903 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL10643586 | 0.87 | LMNA (0.41) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL11483176 | 0.82 | SLC28A1 (0.40) | — | |
| SCHEMBL11489192 | 0.79 | — | — | |
| SCHEMBL766610 | 0.78 | PYGM (0.41) | ALDH1A1LMNAPOLBTK1 | |
| SCHEMBL766611 | 0.78 | PYGM (0.41) | ALDH1A1LMNAPOLBTK1 | |
| SCHEMBL8424715 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL7049183 | 0.77 | ALDH1A1 (0.41) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL766401 | 0.76 | PYGM (0.40) | ALDH1A1LMNAPOLBTK1 | |
| SCHEMBL766461 | 0.76 | PYGM (0.41) | LMNABLMTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274704-B1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | CLARIANT LSM ITALIA SPA (IT) | 2004-01-14 | — | — | EP | claimed |
| EP-1274704-A1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2003-01-15 | — | — | EP | claimed |
| US-6350873-B2 | CHEMICAL INTERMEDIATE FOR STAVUDINE | CLARIANT LIFE SCIENCE MOLECULES (ITALY) S.P.A. (IT) | 2002-02-26 | — | — | US | claimed |
| US-20010039342-A1 | Process for preparing 5'-acetylstavudine | ARCHIMICA S.R.L. (IT) | 2001-11-08 | — | — | US | claimed |
| WO-2001077103-A1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2001-10-18 | — | — | WO | claimed |
| EP-1274704-B1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | CLARIANT LSM ITALIA SPA (IT) | 2004-01-14 | — | — | EP | disclosed |
| EP-1274704-A1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2003-01-15 | — | — | EP | disclosed |
| US-6350873-B2 | CHEMICAL INTERMEDIATE FOR STAVUDINE | CLARIANT LIFE SCIENCE MOLECULES (ITALY) S.P.A. (IT) | 2002-02-26 | — | — | US | disclosed |
| US-20010039342-A1 | Process for preparing 5'-acetylstavudine | ARCHIMICA S.R.L. (IT) | 2001-11-08 | — | — | US | disclosed |
| WO-2001077103-A1 | PROCESS FOR PREPARING 5'-ACETYLSTAVUDINE | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039342-A1 | Process for preparing 5'-acetylstavudine | APRT, SAMHD1, DIMT1 | ALDH1A1 508/4885LMNA 3149/4885ALB 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.